EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report

Qi Yujuan, Ma Xiaozhong, Wu Zhenhua, Bai Yunpeng

Frontiers in Cardiovascular Medicine · 01.08.2025 · 12

DOI: 10.3389/fcvm.2025.1626318 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 01.08.2025. Verfasst von Qi Yujuan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Unit, Chest Hospital Affiliated to Tianjin University, Tianjin, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Entrectinib, a recently approved multikinase inhibitor indicated for advanced ROS1-positive non-small cell lung cancer (NSCLC), has demonstrated significant survival benefits in metastatic disease. However, it carries risks of severe cardiotoxicity. We report the successful management of entrectinib-induced fulminant myocarditis using integrated venoarterial extracorporeal membrane oxygenation (V-A ECMO) and intra-aortic balloon pump (IABP) circulatory support. Case summary A 71-year-old male diagnosed with lung adenocarcinoma three years ago (ROS1-positive on genetic testing) initiated crizotinib therapy. One week prior to admission, surveillance chest computed tomography(CT) revealed disease progression with increased tumor burden, prompting transition to entrectinib. Seven days post-treatment initiation, he presented to our emergency department with acute-onset palpitations, dyspnea, dizziness, and nausea. Emergent coronary angiography excluded significant stenosis. The patient subsequently developed frequent ventricular premature complexes(VPCs), cardiogenic shock (serum lactate 2.6 mmol/L), and acute heart failure. Absent cardiac history and negative viral serology supported a diagnosis of drug-induced fulminant myocarditis. V-A ECMO with IABP support was emergently instituted. Remarkable recovery ensued: cardiac function normalized by day 3 (ECMO decannulation), followed by extubation and IABP removal on day 5.After 12 days of hospitalization, the patient was discharged. Ejection fraction (EF) recovered from 10% at admission to 61% at discharge. Follow-up demonstrates sustained cardiac function comparable to discharge status.

Conclusion

Entrectinib demonstrates potential cardiotoxicity in lung adenocarcinoma therapy, necessitating prospective studies to quantify this risk. During treatment, multidisciplinary team (MDT) collaboration is essential for rigorous cardiac function surveillance. This case establishes V-A ECMO with IABP as an effective salvage therapy for drug-induced fulminant myocarditis.

Schlagwörter

Stichwörter der Autor:innen

cardiogenic shockcase reportentrectinibfulminant myocarditismechanical assistance

Autor:innen und Institutionen

  • Department of Intensive Care Unit, Chest Hospital Affiliated to Tianjin University, Tianjin, China.
  • Department of Intensive Care Unit, Tianjin Chest Hospital, Tianjin, China.
  • Department of Cardiovascular Surgery, Chest Hospital Affiliated to Tianjin University, Tianjin, China.
  • Department of Cardiovascular Surgery, Tianjin Chest Hospital, Tianjin, China.

Zitieren

APA

Yujuan, Q., Xiaozhong, M., Zhenhua, W., & Yunpeng, B. (2025). ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report. Frontiers in Cardiovascular Medicine, 12. https://doi.org/10.3389/fcvm.2025.1626318

Vancouver

Yujuan Q, Xiaozhong M, Zhenhua W, Yunpeng B. ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report. Frontiers in Cardiovascular Medicine. 2025;12. doi:10.3389/fcvm.2025.1626318

BibTeX
@article{Yujuan2025,
  author = {Yujuan, Qi and Xiaozhong, Ma and Zhenhua, Wu and Yunpeng, Bai},
  title = {ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2025},
  volume = {12},
  doi = {10.3389/fcvm.2025.1626318}
}
Kostenlos starten →